Current stock page

Stock Analysis

SELLAS Life Sciences Group, Inc. (SLS) Stock Analysis

SELLAS Life Sciences Group, Inc. (SLS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

SLS Stock Analysis Summary

SELLAS Life Sciences Group, Inc. (SLS) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 73/100. Risk is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

SLS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$7.86
AIQ Score57/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$1.59B
P/E Ratio (TTM)-39.56
Forward P/E—
EPS (Q3 FY2026)-$0.05
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta2.27
Volume11.17M
52-week range$1.39-$15.88
RSI 1434.66
50-Day SMA$11.03
200-Day SMA$8.78
Analyst Price Target—
Next Earnings—
As of Nov 13, 2026 · Market close

SLSSELLAS Life Sciences Group, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

NeutralEdge 9/10
$7.86−$0.17 (−2.12%)

Latest quote

  • Momentum
    55
  • Value
    —
  • Quality
    73
  • Risk resilience
    32
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

SLS Stock Analysis Summary

SELLAS Life Sciences Group, Inc. (SLS) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 73/100. Risk resilience is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, SLS has AIQ Score of 57/100 with Quality base of 73/100 and fading Risk resilience at 32/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (73/100) leads while Risk resilience (32/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.12% stock move · SLS classified in Biotechnology.

Current Evidence

NeutralSLS is in a neutral AIQ regime; Quality is the strongest visible factor at 73/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is SLS Bullish or Bearish Right Now?

SLS currently has a neutral overall setup. Quality is the strongest factor at 73/100, while Risk Resilience is weakest at 32/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 73/100.
Bear Case
  • - Risk Resilience is weak at 32/100.
  • - Price is -10.50% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (37 vs 6).

Current Consensus

SLS's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 3 neutral, and 37 sell votes. SLS's 14-day RSI is 34.66, which places the stock in a weaker momentum range. SLS's beta is 2.27, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in SLS?

The largest recent change in SLS is Momentum moving down by 16.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-7.0
Momentum
-16.0
Quality
-2.0
Risk
+1.0

What Would Change the SLS Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

SLS Decision Framework

Public evidence layers, setup checks, and risk context for SELLAS Life Sciences Group, Inc..

SELLAS Life Sciences Group, Inc. (SLS) Stock Analysis

SELLAS Life Sciences Group, Inc. has an AIQ Score of 57/100 in a Neutral regime. Quality is strongest at 73/100. Beta is 2.27, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextSLS is in a Neutral AIQ regime with score 57/100.
Signal ConflictThe primary conflict is that quality leads at 73/100 while risk lags at 32/100.
Factor EvidenceMomentum 55/100 · Quality 73/100 · Risk 32/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 73/100.

TimingWait

Momentum is 55/100 and RSI (14) is 34.7.

Regime fitWait

SLS is in a Neutral regime at 57/100.

Risk controlFail

Risk factor is 32/100 with beta 2.27 and annual volatility 109.89%.

ConflictWait

Current conflict: quality leads at 73/100 while risk lags at 32/100.

AIQ Score
57/100
Price
$7.86
Beta
2.27
RSI (14)
34.7

SLS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

SLS Fundamentals

SLS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$10.09M
Free cash flow
-$5.94M
View full SLS fundamental analysis

SLS Technical Analysis

SLS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
34.66
Price vs SMA-50
-28.75%
View full SLS technical analysis

SLS Stock Catalysts

Track SLS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
—
Analyst target
—
News items
5
View SLS earnings and stock catalysts

SLS Dividend Analysis

SLS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View SLS dividend history and analysis

SLS Financial Data

SLS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.05
Periods
8
View SLS financials

SLS Risk Analysis

SLS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
2.27
Risk score
32/100
1Y volatility
109.89%
View SLS risk analysis

SLS Stock News

SLS stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read SLS stock news

SLS vs Biotechnology Peers

Current peer cohort: SLS · SMMT · SNDX · SRRK · STOK. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
SLS
Current stock
57/100—55/10032/1002.04109.89%Current
SMMT
Summit Therapeutics Inc.
47/100—65/10038/100-0.0175.92%SLS vs SMMT
SNDX
Syndax Pharmaceuticals, Inc.
43/10064/10014/10037/100-0.7657.16%SLS vs SNDX
SRRK
Scholar Rock Holding Corporation
39/100—54/10052/1000.8457.45%SLS vs SRRK
STOK
Stoke Therapeutics, Inc.
42/10022/10047/10059/1000.2353.19%SLS vs STOK
Pairwise Compare links: SMMT · SNDX · SRRK · STOKSLS vs SMMTSLS vs SNDXSLS vs SRRKSLS vs STOKCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a SLS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for SLS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-39.56
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$10.09M
Quarter free cash flow
-$5.94M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
34.66
MACD
-0.95

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
32/100
Beta
2.27
Annual volatility
109.89%
Max drawdown
-49.16%

SLS Stock FAQ

What is SLS stock price today?

SELLAS Life Sciences Group, Inc.'s current stock price is $7.86. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is SLS bullish or bearish right now?

SLS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is SLS's market cap?

SLS's market cap is $1.59B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is SLS's current P/E ratio?

SLS's current P/E ratio is -39.56 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is SLS's RSI?

SLS's 14-day RSI is 34.66 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is SLS above its 50-day and 200-day moving averages?

SLS is -28.75% from its 50-day SMA and -10.50% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is SLS's next earnings date?

SLS's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does SLS pay a dividend?

SLS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.